WBA icon

Walgreens Boots Alliance

11.01 USD
-0.02
0.18%
At close Apr 25, 4:00 PM EDT
After hours
11.01
+0.00
0.00%
1 day
-0.18%
5 days
1.38%
1 month
-0.99%
3 months
-2.91%
6 months
18.90%
Year to date
19.80%
1 year
-37.44%
5 years
-75.22%
10 years
-87.22%
 

About: Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,000 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.

Employees: 312,000

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

19% more call options, than puts

Call options by funds: $319M | Put options by funds: $268M

11% more first-time investments, than exits

New positions opened: 142 | Existing positions closed: 128

9% more capital invested

Capital invested by funds: $4.56B [Q3] → $4.98B (+$420M) [Q4]

2.83% more ownership

Funds ownership: 59.02% [Q3] → 61.85% (+2.83%) [Q4]

0% less funds holding

Funds holding: 866 [Q3] → 864 (-2) [Q4]

7% less repeat investments, than reductions

Existing positions increased: 284 | Existing positions reduced: 307

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$9
18%
downside
Avg. target
$10.50
5%
downside
High target
$12
9%
upside

2 analyst ratings

positive
0%
neutral
50%
negative
50%
Deutsche Bank
George Hill
78% 1-year accuracy
7 / 9 met price target
18%downside
$9
Sell
Downgraded
28 Feb 2025
Truist Securities
David Macdonald
54% 1-year accuracy
54 / 100 met price target
9%upside
$12
Hold
Maintained
31 Jan 2025

Financial journalist opinion

Based on 50 articles about WBA published over the past 30 days

Neutral
Business Wire
2 days ago
Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is calling on the public to help in the fight against prescription drug abuse by participating in National Prescription Drug Take Back Day on Saturday, April 26th, 2025. Drug take-back days are reserved annually for the safe disposal of unwanted, unused, or expired medications. Walgreens has more than 1,500 kiosks across 46 states and Washington, D.C. These kiosks are a convenient way to ensure medications are not accidentally or intentionally misused.
Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025
Neutral
Business Wire
4 days ago
Walgreens Debuts PharmStart to Strengthen the Tech to Pharmacist Pipeline
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens, the nation's largest independent community pharmacy provider, has teamed up with Guild, the leading talent development company, to launch PharmStart, a first-of-its-kind, fully funded online education program designed to help eligible team members meet the prerequisite requirements for pharmacy school. The program aims to eliminate barriers to pursuing a PharmD degree, tapping into a new pool of talent while also addressing critical challenges in the.
Walgreens Debuts PharmStart to Strengthen the Tech to Pharmacist Pipeline
Negative
The Guardian
4 days ago
Walgreens agrees to pay US up to $350m for illegally filling opioid prescriptions
Drugstore chain settles with DoJ over claims it dispensed millions of unlawful prescriptions for more than a decade
Walgreens agrees to pay US up to $350m for illegally filling opioid prescriptions
Negative
Fox Business
5 days ago
Walgreens to pay up to $350M for filling illegal opioid prescriptions, Justice Department says
Walgreens has agreed to pay up to $350 million to resolve claims that the company illegally filled millions of invalid prescriptions for opioids.
Walgreens to pay up to $350M for filling illegal opioid prescriptions, Justice Department says
Neutral
Business Wire
5 days ago
Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is calling on the public to help in the fight against prescription drug abuse by participating in National Prescription Drug Take Back Day on Saturday, April 26th, 2025. Drug take-back days are reserved annually for the safe disposal of unwanted, unused, or expired medications. Walgreens has more than 1,500 kiosks across 46 states and Washington, D.C. These kiosks are a convenient way to ensure medications are not accidentally or intentionally misused.
Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025
Negative
Reuters
5 days ago
Walgreens settles allegations of filling invalid opioid prescriptions for $300 million, US DOJ says
Walgreens Boots Alliance and its subsidiaries have agreed to pay $300 million to settle U.S. allegations that the pharmacy chain illegally filled millions of invalid prescriptions for opioids and other controlled substances, the U.S. Justice Department said on Monday.
Walgreens settles allegations of filling invalid opioid prescriptions for $300 million, US DOJ says
Positive
Zacks Investment Research
1 week ago
Walgreens Boots Alliance (WBA): Strong Industry, Solid Earnings Estimate Revisions
Walgreens Boots Alliance (WBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Walgreens Boots Alliance (WBA): Strong Industry, Solid Earnings Estimate Revisions
Neutral
Seeking Alpha
1 week ago
Walgreens: Acquisition Is The Best-Case Scenario For The Company
Walgreens Boots Alliance faces significant challenges, including rising inflation, heavy competition, and decreasing profitability, making it a Hold if the acquisition by Sycamore goes through. The company's financial health is concerning, with declining net income, negative free cash flow, and high debt levels, increasing the vulnerability to financial downturns. WBA's lack of its own Pharmacy Benefit Manager (PBM) puts it at a disadvantage compared to CVS, which owns Caremark and can better manage drug prices.
Walgreens: Acquisition Is The Best-Case Scenario For The Company
Positive
MarketBeat
2 weeks ago
Walgreens Comeback? Private Equity Circling for a Buyout
Sometimes, the stock market gives investors the opportunity to play in the corporate leagues, where deals are made not on the stock chart or tape but at the negotiating table when markets are closed and everyone goes home. Today, a potential buyout deal is being discussed by a private equity firm looking to eat up and potentially turn around one of America's darlings in the retail sector, though one that has recently become a sort of “fallen angel,” so to speak.
Walgreens Comeback? Private Equity Circling for a Buyout
Neutral
The Motley Fool
2 weeks ago
Down 89%, Should You Buy the Dip on Walgreens Boots Alliance?
Walgreens Boots Alliance (WBA 0.75%) is in a pending acquisition with Sycamore Partners, a private equity firm, to take the struggling pharmacy chain private. It could end a years-long struggle for the company, which has tried to adapt to modern times and shrinking foot traffic in its stores.
Down 89%, Should You Buy the Dip on Walgreens Boots Alliance?
Charts implemented using Lightweight Charts™